- Home
- IOVA vs WDAY Comparison
IOVA vs WDAY Comparison
Compare IOVA & WDAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- WDAY
- Stock Information
- Founded
- IOVA 2007
- WDAY 2005
- Country
- IOVA United States
- WDAY United States
- Employees
- IOVA N/A
- WDAY N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- WDAY EDP Services
- Sector
- IOVA Health Care
- WDAY Technology
- Exchange
- IOVA Nasdaq
- WDAY Nasdaq
- Market Cap
- IOVA 771.4M
- WDAY N/A
- IPO Year
- IOVA N/A
- WDAY 2012
- Fundamental
- Price
- IOVA $1.89
- WDAY $242.21
- Analyst Decision
- IOVA Buy
- WDAY Buy
- Analyst Count
- IOVA 10
- WDAY 27
- Target Price
- IOVA $12.22
- WDAY $301.85
- AVG Volume (30 Days)
- IOVA 11.2M
- WDAY 2.2M
- Earning Date
- IOVA 08-07-2025
- WDAY 08-21-2025
- Dividend Yield
- IOVA N/A
- WDAY N/A
- EPS Growth
- IOVA N/A
- WDAY N/A
- EPS
- IOVA N/A
- WDAY 1.81
- Revenue
- IOVA $212,679,000.00
- WDAY $8,696,000,000.00
- Revenue This Year
- IOVA $86.62
- WDAY $14.87
- Revenue Next Year
- IOVA $69.95
- WDAY $13.03
- P/E Ratio
- IOVA N/A
- WDAY $132.77
- Revenue Growth
- IOVA 11070.12
- WDAY 14.95
- 52 Week Low
- IOVA $1.64
- WDAY $199.81
- 52 Week High
- IOVA $12.51
- WDAY $294.00
- Technical
- Relative Strength Index (RSI)
- IOVA 47.70
- WDAY 48.72
- Support Level
- IOVA $1.68
- WDAY $237.10
- Resistance Level
- IOVA $1.82
- WDAY $242.78
- Average True Range (ATR)
- IOVA 0.11
- WDAY 4.73
- MACD
- IOVA 0.02
- WDAY 0.62
- Stochastic Oscillator
- IOVA 51.14
- WDAY 88.84
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.